Evidence map›Paper›PMID 29653065›Full record

ReviewDNA and cell biology2018

TET2: A Novel Epigenetic Regulator and Potential Intervention Target for Atherosclerosis.

Yami Liu, Wen Peng, Kai Qu, Xiaolong Lin, Zhaolin Zeng, Jiaojiao Chen, Dangheng Wei, Zuo Wang

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in DNA and cell biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Review
  12. Article
  13. N6-Methyladenosine RNA Methylation in Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2022
    Review
  14. DNA Methylation Aberrant in Atherosclerosis.Frontiers in pharmacology · 2022
    Review
  15. Article
  16. Contributions of Costimulatory Molecule CD137 in Endothelial Cells.Journal of the American Heart Association · 2021
    Review
  17. Article
  18. Article
  19. DNA Methylation in Atherosclerosis: A New Perspective.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yami Liu1 Key Laboratory for Atherosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South China , Hengyang, China .
Wen Peng2 Department of Spine Surgery, The First Affiliated Hospital, University of South China , Hengyang, China .
Kai Qu3 College of Bioengineering, Chongqing University , Chongqing, China .
Xiaolong Lin4 Department of Pathology, The Third People's Hospital of Huizhou , Huizhou, China .
Zhaolin Zeng1 Key Laboratory for Atherosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South China , Hengyang, China .
Jiaojiao Chen1 Key Laboratory for Atherosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South China , Hengyang, China .
Dangheng Wei1 Key Laboratory for Atherosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South China , Hengyang, China .
Zuo Wang1 Key Laboratory for Atherosclerology of Hunan Province, Institute of Cardiovascular Disease, University of South China , Hengyang, China .
University of South China · CNChongqing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis is the underlying cause of cardio-cerebrovascular disease. However, the mechanisms of atherosclerosis are still unclear. The modification of DNA methylation has an important role in atherosclerosis development. As a member of the Ten-eleven translocation (TET) family, TET methylcytosine dioxygenase 2 (TET2) can modify DNA methylation by catalyzing 5-methylcytosine to 5-hydroxymethylcytosine and mediate DNA demethylation. Recent findings suggest that TET2 is related to the phenotype transformation of vascular smooth muscle cells, endothelial dysfunction, and inflammation of macrophage, the key factors of atherosclerosis. Therefore, TET2 may be a potential target for atherosclerosis treatment. This review will elaborate the recent findings that suggest the role of TET2 in atherosclerosis.

Indexed as

DNA MethylationEpigenesis, GeneticAtherosclerosisDioxygenasesDNA-Binding ProteinsEndothelial CellsGene Expression RegulationHumansInflammationMuscle, Smooth, VascularMyocytes, Smooth MuscleProto-Oncogene ProteinsDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, humanatherosclerosisDNA demethylationinflammationTET2

Identifiers

PMID29653065
PMCPMC5985959
OpenAlexW2798032967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.